Answers are grounded in this paper and cite their sources.
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
No takes yet. Share an insight, caveat, or question.
Gradoni et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: